Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
Status:
Withdrawn
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study is a proof-of-concept clinical study designed to test the hypothesis that oral
administration of galactose can lower the level of a circulating factor that increases
glomerular permeability to albumin in patients with resistant FSGS.